The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).

/by

Authors: George A. Fraser
CNS Neuroscience & Therapeutics, Winter 2009
—
This is the report of an open label clinical trial to evaluate the effects of nabilone, an endocannabinoid receptor agonist, on treatment-resistant nightmares in patients diagnosed with posttraumatic stress disorder (PTSD). METHODS: Charts of 47 patients diagnosed with PTSD an…

Read more

Association of the cannabinoid receptor gene (CNR1) with ADHD and post‐traumatic stress disorder.

/by

Authors: Ake T. Lu, Matthew N. Ogdie, Marjo‐Ritta Järvelin, Irma K. Moilanen, Sandra K. Loo, et al
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 22 January 2008
—
Attention deficit hyperactivity disorder (ADHD) is a highly heritable disorder affecting some 5-10% of children and 4-5% of adults. The cannabinoid receptor gene (CNR1) is a positional candidate gene due to its location near an identified ADHD linkage peak on chromosome 6, its…

Read more